144 related articles for article (PubMed ID: 35224510)
1. Anti-Cancer Activity of PAK4/NAMPT Inhibitor and Programmed Cell Death Protein-1 Antibody in Kidney Cancer.
Trott JF; Aboud OA; McLaughlin B; Anderson KL; Modiano JF; Kim K; Jen KY; Senapedis W; Chang H; Landesman Y; Baloglu E; Pili R; Weiss RH
Kidney360; 2020 May; 1(5):376-388. PubMed ID: 35224510
[TBL] [Abstract][Full Text] [Related]
2. Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.
Abu Aboud O; Chen CH; Senapedis W; Baloglu E; Argueta C; Weiss RH
Mol Cancer Ther; 2016 Sep; 15(9):2119-29. PubMed ID: 27390344
[TBL] [Abstract][Full Text] [Related]
3. KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells.
Cordover E; Wei J; Patel C; Shan NL; Gionco J; Sargsyan D; Wu R; Cai L; Kong AN; Jacinto E; Minden A
Chem Res Toxicol; 2020 Feb; 33(2):482-491. PubMed ID: 31876149
[TBL] [Abstract][Full Text] [Related]
4. Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia.
Li N; Lopez MA; Linares M; Kumar S; Oliva S; Martinez-Lopez J; Xu L; Xu Y; Perini T; Senapedis W; Baloglu E; Shammas MA; Hunter Z; Anderson KC; Treon SP; Munshi NC; Fulciniti M
Clin Cancer Res; 2019 Jan; 25(1):369-377. PubMed ID: 30206161
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation.
Mitchell S; Zhang P; Cannon M; Beaver L; Lehman A; Harrington B; Sampath D; Byrd JC; Lapalombella R
J Hematol Oncol; 2021 Jun; 14(1):101. PubMed ID: 34187548
[TBL] [Abstract][Full Text] [Related]
6. Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma.
Hirayama Y; Gi M; Yamano S; Tachibana H; Okuno T; Tamada S; Nakatani T; Wanibuchi H
Cancer Sci; 2016 Dec; 107(12):1736-1744. PubMed ID: 27712020
[TBL] [Abstract][Full Text] [Related]
7. Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth.
Wettersten HI; Landesman Y; Friedlander S; Shacham S; Kauffman M; Weiss RH
PLoS One; 2014; 9(12):e113867. PubMed ID: 25461627
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model.
Hara T; Miyake H; Hinata N; Fujisawa M
Anticancer Res; 2019 Sep; 39(9):4737-4742. PubMed ID: 31519573
[TBL] [Abstract][Full Text] [Related]
9. Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.
Fan K; Zhou M; Pathak MK; Lindner DJ; Altuntas CZ; Tuohy VK; Borden EC; Yi T
J Immunol; 2005 Nov; 175(10):7003-8. PubMed ID: 16272361
[TBL] [Abstract][Full Text] [Related]
10. PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors.
Mpilla G; Aboukameel A; Muqbil I; Kim S; Beydoun R; Philip PA; Mohammad RM; Kamgar M; Shidham V; Senapedis W; Baloglu E; Li J; Dyson G; Xue Y; El-Rayes B; Azmi AS
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31795447
[TBL] [Abstract][Full Text] [Related]
11. Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.
Hwang VJ; Zhou X; Chen X; Trott J; Abu Aboud O; Shim K; Dionne LK; Chmiel KJ; Senapedis W; Baloglu E; Mahjoub MR; Li X; Weiss RH
Kidney Int; 2017 Oct; 92(4):922-933. PubMed ID: 28545714
[TBL] [Abstract][Full Text] [Related]
12. Targeting the vulnerability to NAD
Takao S; Chien W; Madan V; Lin DC; Ding LW; Sun QY; Mayakonda A; Sudo M; Xu L; Chen Y; Jiang YY; Gery S; Lill M; Park E; Senapedis W; Baloglu E; Müschen M; Koeffler HP
Leukemia; 2018 Mar; 32(3):616-625. PubMed ID: 28904384
[TBL] [Abstract][Full Text] [Related]
13. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
14. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
15. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
Ellis L; Shah P; Hammers H; Lehet K; Sotomayor P; Azabdaftari G; Seshadri M; Pili R
Mol Cancer Ther; 2012 Feb; 11(2):383-92. PubMed ID: 22084164
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of anti-cancer potency of silibinin on murine renal carcinoma RenCa cells in an animal model with an intact immune system.
Yang C; Li F; Ma J; Zhang HB; Jia J; Zeng J; Wang X; He D; Guo P
Anticancer Drugs; 2020 Sep; 31(8):785-791. PubMed ID: 32209841
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma.
Li X; Xu P; Wang C; Xu N; Xu A; Xu Y; Sadahira T; Araki M; Wada K; Matsuura E; Watanabe M; Zheng J; Sun P; Huang P; Nasu Y; Liu C
Oncotarget; 2017 Mar; 8(13):21177-21186. PubMed ID: 28416753
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
Chang YS; Adnane J; Trail PA; Levy J; Henderson A; Xue D; Bortolon E; Ichetovkin M; Chen C; McNabola A; Wilkie D; Carter CA; Taylor IC; Lynch M; Wilhelm S
Cancer Chemother Pharmacol; 2007 Apr; 59(5):561-74. PubMed ID: 17160391
[TBL] [Abstract][Full Text] [Related]
19. PAK4 and NAMPT as Novel Therapeutic Targets in Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma.
Khan HY; Uddin MH; Balasubramanian SK; Sulaiman N; Iqbal M; Chaker M; Aboukameel A; Li Y; Senapedis W; Baloglu E; Mohammad RM; Zonder J; Azmi AS
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008323
[TBL] [Abstract][Full Text] [Related]
20. Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
Lee J; Kim H; Lee JE; Shin SJ; Oh S; Kwon G; Kim H; Choi YY; White MA; Paik S; Cheong JH; Kim HS
Gastroenterology; 2018 Sep; 155(3):799-814.e13. PubMed ID: 29775598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]